BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 36367834)

  • 1. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
    Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
    Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
    Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
    Martinez F; Clua E; Roca M; Garcia S; Polyzos NP
    Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of letrozole co-treatment during ovarian stimulation on oocyte yield, embryo development, and live birth rate in women with normal ovarian reserve: secondary outcomes from the RIOT trial.
    Bülow NS; Warzecha AK; Nielsen MV; Andersen CY; Holt MD; Petersen MR; Sopa N; Zedeler A; Englund AL; Pinborg A; Grøndahl ML; Skouby SO; Macklon NS
    Hum Reprod; 2023 Nov; 38(11):2154-2165. PubMed ID: 37699851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
    Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
    Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
    Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
    Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
    Bülow NS; Skouby SO; Warzecha AK; Udengaard H; Andersen CY; Holt MD; Grøndahl ML; Nyboe Andersen A; Sopa N; Mikkelsen ALE; Pinborg A; Macklon NS
    Hum Reprod; 2022 Jan; 37(2):309-321. PubMed ID: 34792133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of letrozole cotreatment on endocrinology and follicle development in women undergoing ovarian stimulation in an antagonist protocol.
    Poulsen LC; Warzecha AK; Bülow NS; Bungum L; Macklon NS; Yding Andersen C; Skouby SO
    Hum Reprod; 2022 Jun; 37(7):1557-1571. PubMed ID: 35652260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.
    Friis Wang N; Skouby SO; Humaidan P; Andersen CY
    Hum Reprod; 2019 May; 34(5):942-948. PubMed ID: 30927415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates.
    Uyanik E; Mumusoglu S; Polat M; Yarali Ozbek I; Esteves SC; Humaidan P; Yarali H
    Hum Reprod; 2023 Feb; 38(2):225-236. PubMed ID: 36478179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
    Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
    Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FSH Stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization.
    Oktem O; Akin N; Bildik G; Yakin K; Alper E; Balaban B; Urman B
    Hum Reprod; 2017 Mar; 32(3):643-652. PubMed ID: 28158500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: a randomized controlled trial.
    Zhang S; Tang Y; Wang X; Zong Y; Li X; Cai S; Ma H; Guo H; Song J; Lin G; Lu G; Gong F
    Hum Reprod; 2022 Jun; 37(7):1431-1439. PubMed ID: 35460400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.